You are here

CULTURED CILIATED CELLS FOR HIGH THROUGHPUT SCREENING

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 2R44HL067595-02A1
Agency Tracking Number: HL067595
Amount: $764,660.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BIOTECHPLEX CORPORATION 755 NICHOLAS BLVD
ELK GROVE VILLAGE, IL 60007
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 HUA MAO
 (847) 437-9300
 HMAO@BIOTECHPLEX.COM
Business Contact
 DONOVAN YEATES
Phone: (847) 437-9300
Email: DYEATES@BIOTECHPLEX.COM
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): BioTechPlex proposes to develop mammalian tracheal/bronchial airway epithelial cell line, CILSCREEN TM, specifically for high throughput screening. This is based on physiological functional assays. BioTechPlex has accomplished all the proposed Phase I objectives. A) Successfully developed techniques to culture and numerically expand airway epithelial cells while preserving ciliogenesis and ciliary function. B) Developed methodologies to reactivate mechanisms of ciliogenesis to regenerate the cilia following loss of cilia induced by submerged culture. C) Developed methodologies to induce cell polarization so as to induce cilia outgrowth on more than 50 percent of epithelial cells, which maintained normal ciliary beating for at least 3-4 weeks. In this Phase II project, BioTechPlex will incorporate and extend the accomplishments of Phase I to produce viable commercial cell lines in five species to form the first Mammalian Ciliated Cell Bank. Specifically, BioTechPlex will accomplish the following objectives. 1). Further identify factors regulating cell division and differentiation. 2). Produce large quantities of airway epithelial ciliated cells. 3). Characterize the cell lines using biomarkers, morphological characteristics and physiological function, and 4). Establish a Mammalian Ciliated Cell Bank. BioTechPlex plans to facilitate widespread use of airway ciliated epithelial cells for cell function studies, i.e. the cells will become an alternative to the use of fibroblasts, tumor cell lines and other genetically altered cell lines utilized in high throughput screening for pulmonary drug discovery. These cell model systems will be suitable for the study of normal and induced pathological mechanisms and their related pharmacology.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government